Non-peptide

Sotatercept

Also known as

Winrevair · ACE-011 (related) · sotatercept-csrk

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Winrevair	A prescription signal-trapping protein for pulmonary arterial hypertension, meaning high pressure in lung arteries. It is injected under the skin.
PAH treatment context	It is an addition to existing disease treatment. Adult PAH evidence concerns exercise capacity and worsening, rather than muscle gain or soft-tissue recovery.

Notes

Sotatercept (Winrevair) is a prescription protein for pulmonary arterial hypertension (PAH). Patients report easier breathing, persistent fatigue, no noticeable improvement or troublesome side effects.

A signal trap. The protein joins an activin-receptor segment to an antibody fragment and binds signaling molecules involved in blood-vessel changes. It is injected under the skin. PAH is a disease of the lung arteries with abnormally high pressure; this treatment context differs from general breathlessness. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

An addition to an existing treatment picture. Forum patients describe taking it alongside Remodulin, ambrisentan and tadalafil. One reports easier breathing but continuing exhaustion with Hashimoto’s and fibromyalgia. The experience involves a disease, other medicines and other symptoms, not a clean test of one substance. Sotatercept/Winrevair (Community discussion · Accessed 2026-09-30)

Adult PAH evidence. Trials support exercise capacity and reduced worsening, not muscle gain or soft-tissue recovery. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Source context — FDA WINREVAIR prescribing information, revised March 2026: Manufacturer-authored regulated document; all mirrors/reprints share this source origin. Supports medical context, not community protocols or bodybuilding claims. Half-life and concentration timing are separate from experience. Animal-based fetal/fertility risk remains identified.

Source context — Sotatercept/Winrevair: Patient discussion hosted by a commercial health-media site; moderator encouragement is not evidence of effectiveness. Kit amount is not administered dose. Some units are wrong or ambiguous; no conversion inferred. Date belongs to thread opening, not every reply.

What people notice

Easier breathing	Some patients describe faster chores, calmer heartbeat or improvement around the third or fourth injection.
Energy can differ	More energy after dose two, months of fluctuating energy and no energy improvement after three doses all appear. Easier breathing can coexist with fatigue or leg weakness.

Notes

Less breathlessness in ordinary activity. One Reddit patient reports a calmer heartbeat and faster chores from day one; another improved around injection three or four. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

Good tests and feeling better can diverge. The My Journey author describes manageable breathlessness while risk scoring is unchanged and walking-test performance has declined. Their Remodulin infusion and oral therapy make attribution to Sotatercept impossible. A separate minimally symptomatic patient reports no felt difference, showing why a subjective “nothing happened” account needs its starting context. My Journey (Personal report · Accessed 2026-09-30) · Winrevair: energy-level experiences (Community discussion · Accessed 2026-09-30)

Energy is a separate question. One patient reports more energy after dose two; another needed months and still fluctuates. Better breathing with major leg weakness also appears. Winrevair: energy-level experiences (Community discussion · Accessed 2026-09-30)

No energy improvement after three doses also appears. The same initiating author posts first-dose disappointment, then no improvement after two doses with harder breathing, and finally no energy change after three. They did not attribute the worsening breathing to Winrevair. This is one continuing account. Winrevair: energy-level experiences (Community discussion · Accessed 2026-09-30)

Source context — What has been you experience with Winrevair?: Anonymous reports, unverified diagnoses and co-medications. Hidden More replies were not inspected. Cross-thread repeat authors are not independent confirmations. No prevalence or measured kinetics.

Source context — My Journey: Self-reported combination treatment. Same kablekompany also comments in severe PAH; not counted twice. Patient language cannot establish a causal Sotatercept outcome.

Source context — Winrevair: energy-level experiences: Same initiator as the experience thread, and some same commenters; chronology is one account, not multiple patients. Seven/eight-dose statement is secondhand and not used as measured onset. Iron explanation is unverified community speculation and omitted as causal fact.

Doses people talk about

Patient accounts	Injection every 21 days is reported, without administered milligrams. A 90 mg kit or an ambiguous “90 ml kit” does not establish the injected amount.
Separate label context	0.3 mg/kg starting amount, then 0.7 mg/kg per SubQ injection every three weeks when blood counts permit. These are specialist-managed label amounts.

Notes

Injection every 21 days appears in patient accounts. A Reddit patient describes Sotatercept on that schedule alongside continuous Remodulin and oral Opsynvi. The post does not state the Sotatercept milligrams. This is a report of prescribed treatment, not a daily peptide amount. My Journey (Personal report · Accessed 2026-09-30)

Kit strength does not establish the injected dose. A forum participant mentions a 90 mg kit without giving the administered amount. Another writes “90 ml kit”; that ambiguous unit cannot support a dose calculation. These posts do not establish a community mg/kg range. Sotatercept/Winrevair (Community discussion · Accessed 2026-09-30)

Medical amounts. The label specifies a starting amount of 0.3 mg/kg and a target of 0.7 mg/kg per under-skin injection every three weeks when blood counts permit. These are specialist-managed treatment amounts. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Labeled starting dose: 0.3 mg/kg by subcutaneous injection once, followed three weeks later by escalation only after acceptable hemoglobin and platelet counts. [trial]

Labeled target dose: 0.7 mg/kg by subcutaneous injection every three weeks unless label-defined laboratory changes require delay or adjustment. [trial]

Half-life, onset & duration

Felt onset	Reports range from day one to the third/fourth injection or roughly three months. No predictable personal onset emerges.
Felt duration	One patient describes roughly two better weeks; another reports harder stairs near the next injection. Neither measures clearance or after-stopping benefit.
Half-life	About 24 days effective half-life in human PAH research. This measured value is separate from feeling a dose wear off.
Blood peak	Median seven days after repeated four-week dosing in the label's study context; steady levels took about 15 weeks. These are concentration timings, not felt onset.

Notes

Immediate change through roughly three months. The competing reports above do not establish predictable onset. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30) · Winrevair: energy-level experiences (Community discussion · Accessed 2026-09-30)

One patient: roughly two better weeks. Kathleen Grady’s benefit fades; early headaches later resolved. Separately, a Reddit patient reports harder stairs near the next injection. Neither measures clearance. Winrevair (Sotatarcept) Side Effects (Community discussion · Accessed 2026-09-30) · What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

A year of follow-up is not an after-stopping window. One continuing patient reports improved breathing and palpitations but persistent fatigue. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

Measured timing is separate. Effective half-life: about 24 days; median peak: seven days after repeated four-week dosing; stable levels: about 15 weeks. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Wearing off does not measure half-life. A Reddit reply asks about this connection. No patient-measured half-life appears; formal figures remain separately labeled below. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

Source context — Winrevair (Sotatarcept) Side Effects: Commercial host, user content. Exact diagnoses/medications cannot be verified; moderator advice and universal BP claims are not accepted. Ambiguous unitless 1.7 and pediatric dose do not establish an adult community dose band. Only visible replies inspected.

Cycles people discuss

Ongoing prescribed treatment	Patient accounts describe continued treatment, usually at 21-day intervals, rather than a weeks-on/weeks-off cycle.
Medical pauses or adjustments	Rising hemoglobin led to a paused injection in one account; another family remained at the starting amount. These are medical changes rather than tolerance breaks.

Notes

Patient accounts describe continued treatment. The 21-day account describes ongoing combination care. In another discussion, a parent reports two lower starting doses about five weeks apart in a complex case involving leukemia and valve damage. That interval is not a planned on/off cycle. My Journey (Personal report · Accessed 2026-09-30) · severe PAH (Community discussion · Accessed 2026-09-30)

Blood results can interrupt the schedule. Roxanne Giustini describes a second injection being paused after hemoglobin rose on two successive checks. Another family reports remaining at the starting amount rather than increasing it. These are medical adjustments, not tolerance breaks or bodybuilding cycling. Winrevair (Sotatarcept) Side Effects (Community discussion · Accessed 2026-09-30)

Source context — severe PAH: Family report, unclear PH classification in complex valve/leukemia case; patient admitted uncertainty over causation. Promotional-sounding miracle language is not adopted. Facebook groups recommended by a commenter were not accessed.

Stacks

Background PAH medicines	Patients describe Remodulin, ambrisentan and tadalafil. A 21-day account also used continuous Remodulin and oral Opsynvi; the combination belongs to a specialist treatment plan.
Bleeding context	Background prostacyclin or antithrombotic treatment can also affect bleeding risk. The reports do not establish a harmless combination.

Notes

PAH background therapy: Sotatercept was studied and is used as an add-on to established PAH therapies; the combination and monitoring plan belongs to the treating specialist. [trial]

Not a solo research run: Sotatercept is a serious prescription biologic used within a PAH treatment plan; background prostacyclin or antithrombotic therapy can also affect bleeding risk. [trial]

Blood counts and bleeding. Excess red cells, clots, low platelets and serious bleeding are risks; prostacyclins and blood thinners add concern. Check hemoglobin and platelets before each of the first five doses, longer if unstable, periodically afterward. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Watch for

Blood counts and bleeding	Excess red cells, clots, low platelets and serious bleeding are risks. The label requires hemoglobin/platelet monitoring; severe nosebleeds appeared around month four in one account.
Headache, fatigue and other reactions	Headache, diarrhea, rash, itching, fatigue and nose/gum bleeding appear. Some symptoms ease, while others persist or have other medicines involved.
Oxygenation concerns	The label describes shunts that bypass lung oxygen exchange despite improved pressures; voluntary reports cannot establish their frequency.
Pregnancy and fertility	Animal data warn of fetal harm and impaired fertility. The label includes pregnancy testing, contraception and no breastfeeding through treatment and four months afterward.

Notes

Bleeding can appear months later. A spouse reports severe nosebleeds around month four, stopping after treatment stopped. Initial tolerability did not persist; one account cannot estimate risk. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

Labeled reactions. Headache, diarrhea, rash, redness, spider veins, dizziness, infections and nose/gum bleeding appear in the label. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Fatigue, headaches and diarrhea after injection. A fourth-dose Reddit report includes vaccine-like tiredness; lupus and Evans syndrome complicate attribution. What has been you experience with Winrevair? (Community discussion · Accessed 2026-09-30)

Some symptoms ease while others persist. Diana’s forum account describes itching easing after about a week, headaches persisting and diarrhea improving after another medicine was adjusted. That is one timeline, not evidence all side effects fade. Winrevair (Sotatarcept) Side Effects (Community discussion · Accessed 2026-09-30)

Better pressures leave other risks. SOTERIA and postmarketing shunt reports describe blood bypassing lung oxygen exchange despite better pressures. The label separately lists postmarketing pericardial effusion, fluid around the heart. Voluntary reports cannot establish frequency or causality. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Pregnancy and fertility. Animal data warn of fetal harm and fertility impairment. Pregnancy testing is needed; contraception and no breastfeeding continue through treatment and four months afterward. FDA WINREVAIR prescribing information, revised March 2026 (Official context · Accessed 2026-09-30)

Full notes

What Sotatercept actually is

A signal trap. The protein joins an activin-receptor segment to an antibody fragment and binds signaling molecules involved in blood-vessel changes. It is injected under the skin. PAH is a disease of the lung arteries with abnormally high pressure; this treatment context differs from general breathlessness. Official context
An addition to an existing treatment picture. Forum patients describe taking it alongside Remodulin, ambrisentan and tadalafil. One reports easier breathing but continuing exhaustion with Hashimoto’s and fibromyalgia. The experience involves a disease, other medicines and other symptoms, not a clean test of one substance. Pulmonary Hypertension News patient forum

What patients hope to get from it

Less breathlessness in ordinary activity. One Reddit patient reports a calmer heartbeat and faster chores from day one; another improved around injection three or four. Reddit r/PulmonaryHypertension
Energy is a separate question. One patient reports more energy after dose two; another needed months and still fluctuates. Better breathing with major leg weakness also appears. Reddit r/PulmonaryHypertension

Doses patients discuss

Injection every 21 days appears in patient accounts. A Reddit patient describes Sotatercept on that schedule alongside continuous Remodulin and oral Opsynvi. The post does not state the Sotatercept milligrams. This is a report of prescribed treatment, not a daily peptide amount. Personal report
Kit strength does not establish the injected dose. A forum participant mentions a 90 mg kit without giving the administered amount. Another writes “90 ml kit”; that ambiguous unit cannot support a dose calculation. These posts do not establish a community mg/kg range. Pulmonary Hypertension News patient forum

Half-life and community interpretations

Wearing off does not measure half-life. A Reddit reply asks about this connection. No patient-measured half-life appears; formal figures remain separately labeled below. Reddit r/PulmonaryHypertension

When patients notice a difference

Immediate change through roughly three months. The competing reports above do not establish predictable onset. Reddit r/PulmonaryHypertension Reddit r/PulmonaryHypertension
No energy improvement after three doses also appears. The same initiating author posts first-dose disappointment, then no improvement after two doses with harder breathing, and finally no energy change after three. They did not attribute the worsening breathing to Winrevair. This is one continuing account. Reddit r/PulmonaryHypertension

How long a noticeable benefit lasts

One patient: roughly two better weeks. Kathleen Grady’s benefit fades; early headaches later resolved. Separately, a Reddit patient reports harder stairs near the next injection. Neither measures clearance. Pulmonary Hypertension News patient forum Reddit r/PulmonaryHypertension
A year of follow-up is not an after-stopping window. One continuing patient reports improved breathing and palpitations but persistent fatigue. Reddit r/PulmonaryHypertension

Continuing treatment and interruptions

Patient accounts describe continued treatment. The 21-day account describes ongoing combination care. In another discussion, a parent reports two lower starting doses about five weeks apart in a complex case involving leukemia and valve damage. That interval is not a planned on/off cycle. Personal report Reddit r/PulmonaryHypertension
Blood results can interrupt the schedule. Roxanne Giustini describes a second injection being paused after hemoglobin rose on two successive checks. Another family reports remaining at the starting amount rather than increasing it. These are medical adjustments, not tolerance breaks or bodybuilding cycling. Pulmonary Hypertension News patient forum

Cautions that matter

Blood counts and bleeding. Excess red cells, clots, low platelets and serious bleeding are risks; prostacyclins and blood thinners add concern. Check hemoglobin and platelets before each of the first five doses, longer if unstable, periodically afterward. Official context
Pregnancy and fertility. Animal data warn of fetal harm and fertility impairment. Pregnancy testing is needed; contraception and no breastfeeding continue through treatment and four months afterward. Official context
Better pressures leave other risks. SOTERIA and postmarketing shunt reports describe blood bypassing lung oxygen exchange despite better pressures. The label separately lists postmarketing pericardial effusion, fluid around the heart. Voluntary reports cannot establish frequency or causality. Official context
Labeled reactions. Headache, diarrhea, rash, redness, spider veins, dizziness, infections and nose/gum bleeding appear in the label. Official context
Bleeding can appear months later. A spouse reports severe nosebleeds around month four, stopping after treatment stopped. Initial tolerability did not persist; one account cannot estimate risk. Reddit r/PulmonaryHypertension

Separately labeled medical context

Medical amounts. The label specifies a starting amount of 0.3 mg/kg and a target of 0.7 mg/kg per under-skin injection every three weeks when blood counts permit. These are specialist-managed treatment amounts. Official context
Measured timing is separate. Effective half-life: about 24 days; median peak: seven days after repeated four-week dosing; stable levels: about 15 weeks. Official context
Adult PAH evidence. Trials support exercise capacity and reduced worsening, not muscle gain or soft-tissue recovery. Official context

What the mixed experiences add

Good tests and feeling better can diverge. The My Journey author describes manageable breathlessness while risk scoring is unchanged and walking-test performance has declined. Their Remodulin infusion and oral therapy make attribution to Sotatercept impossible. A separate minimally symptomatic patient reports no felt difference, showing why a subjective “nothing happened” account needs its starting context. Personal report Reddit r/PulmonaryHypertension
Recovery stories still have other causes in play. The parent in the severe-PAH thread reports greatly improved pressures and later follow-up, but also says heart recovery began before Winrevair. Leukemia, valve disease and sildenafil remain part of that same story. Calling it a drug-alone reversal would erase the account’s own qualification. These accounts cannot settle long-term benefits or risks. Reddit r/PulmonaryHypertension
Fatigue, headaches and diarrhea after injection. A fourth-dose Reddit report includes vaccine-like tiredness; lupus and Evans syndrome complicate attribution. Reddit r/PulmonaryHypertension
Some symptoms ease while others persist. Diana’s forum account describes itching easing after about a week, headaches persisting and diarrhea improving after another medicine was adjusted. That is one timeline, not evidence all side effects fade. Pulmonary Hypertension News patient forum